Biotech Values

[DewDiligence]

IOVA—The clinical-data PR came first (4:01pm ET); the financing PR came second (4:20pm ET):

https://www.globenewswire.com/news-release/2020/05/27/2039716/0/en/Iovance-Reports-Pivotal-Cohort-4-Data-for-Tumor-Infiltrating-Lymphocyte-TIL-Therapy-Lifileucel-from-C-144-01-Clinical-Study-in-Advanced-Melanoma.html

https://www.globenewswire.com/news-release/2020/05/27/2039756/0/en/Iovance-Biotherapeutics-Inc-Announces-Proposed-Public-Offering-of-Common-Stock.html

Nevertheless, I concur that the timing of the two PRs is odd. Normally, companies allow investors more time for (purportedly) positive clinical data to sink in.